Arun Rajasekaran, MD, FACP, FASN, FNKF

Nephrologist @RMANewMexico. GN aficionado. Principal Investigator. Clinical Trialist

[Izabela Zakrocka @IzabelaZakrocka]

Never say never 👀 thanks for a great transplant case ✨@Rush_Nephrology @NephRodby @TWhittier_RUSH @Proximal_Baxi @BajinderR

[Arun Rajasekaran, MD, FACP, FASN, FNKF @Nephronpower]

@NephRodby @TWhittier_RUSH Great case and discussion as always :)

[Roger Rodby @NephRodby]

Starts in 4 hours. This transplant case just gets better and better the more we delved into it!

[Arun Rajasekaran, MD, FACP, FASN, FNKF @Nephronpower]

@SaynaNorouzi @ERAkidney @DanaRizk1 All star team

[Sayna Norouzi, MD, FASN @SaynaNorouzi]

Thanks for having me!! @ERAkidney
Fantastic session chaired by the amazing @DanaRizk1 on complements and IgAN. ⭐️🫶
Time to level up the conversations ;)
#RareKidneyDisease #IgAN #ERA26

[Sayna Norouzi, MD, FASN @SaynaNorouzi]

AI feedback vs. human feedback >> we put it to the test ⭐️
At @GlomCon Fellowship, we care about how we teach, not just what we teach. So we studied one of the most overlooked skills: giving great feedback.
See the details here👇
https://t.co/xi4GRwsMwH

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Diabetic Nephropathy (DN) with concurrent primary podocytopathy represents a distinct clinical entity characterized by nephrotic-range proteinuria, ultrastructural podocyte effacement and favorable response to immunosuppressive therapy ca. 2026 from @NDTsocial
#Nephpearls #ECNeph

Early renal biopsy incorporating Foot Process Width (FPW) assessment enables targeted therapy to mitigate ESKD progression in this high-risk phenotype.

https://t.co/tdJLMh1zMd

[Sara Almutar @s_almutar]

Excited to share that our #GlomConHawaii meeting report is now published in Rare Kidney Disease!

Honored to have been part of such an incredible group and looking forward to what’s ahead and the next @GlomCon Hawaii 2026! 🌺

[Arun Rajasekaran, MD, FACP, FASN, FNKF @Nephronpower]

@asnpublications @kantsmd @svuh @ucddublin Great choice, congratulations @kantsmd

[Arun Rajasekaran, MD, FACP, FASN, FNKF @Nephronpower]

RT @edgarvlermamd: Glomerular frontiers: consensus perspectives from @GlomCon @n0r0zha @poyanmehr @haresh11 @BetterCallSeeth @zainabo87 @NW…

[Zainab Obaidi @zainabo87]

Thrilled to see our #GlomConHawaii meeting report officially published in Rare Kidney Disease! Proud of the hard work put in alongside amazing colleagues!
Looking forward to seeing what #GlomCon2026 has in store! 🌺☀️🌊

[bajinder reen @BajinderR]

@zainabo87 @IzabelaZakrocka @NephRodby @TWhittier_RUSH @Proximal_Baxi @Rush_Nephrology @Nephronpower Join me on june3 at 6pm edt Presenting very unusual case

[Sayna Norouzi, MD, FASN @SaynaNorouzi]

Our meeting report from #GlomConHawaii is now published in Rare Kidney Disease the official journal of @GlomCon!

And the next #GlomConHawaii is already on the horizon 🌺👇

https://t.co/JuKxbvVXHJ

#RareKidneyDisease #Glomerulonephritis #Nephrology #GlomCon
@edgarvlermamd @AKronbichler @poyanmehr @SwatiAr76730089 @NWiegley @BetterCallSeeth @zainabo87 @s_almutar @Nephronpower ⭐️

[Arun Rajasekaran, MD, FACP, FASN, FNKF @Nephronpower]

@IzabelaZakrocka @NephRodby @TWhittier_RUSH @Proximal_Baxi @Rush_Nephrology @BajinderR @zainabo87 Great case @Proximal_Baxi. Always appreciate the dedication and passion of the Rush folks @Rush_Nephrology @NephRodby @TWhittier_RUSH, Casey Gashti, Steve Corbett, @Proximal_Baxi

[Andrea Angioi, MD, FASN @andreaangioi]

Most kidney trials whisper.
This one doesn’t.

@NEJM Phase 3 interim analysis in NEJM:
telitacicept cut proteinuria by 58.9% vs 8.8% placebo in high-risk IgA nephropathy.

eGFR at 39 weeks: -1.0% vs -7.7%.

Dual BAFF/APRIL blockade may be hitting disease upstream.
#IgAN #Nephrology #KidneyDisease #Glomerulonephritis

[Kenar Jhaveri @kdjhaveri]

Yet another IgAN drug on the way https://t.co/mJGbz73Dch @NEJM

[Arun Rajasekaran, MD, FACP, FASN, FNKF @Nephronpower]

https://t.co/yRYmvCJ89i

[Arun Rajasekaran, MD, FACP, FASN, FNKF @Nephronpower]

Our publication evaluating serum phospholipase A2 receptor antibody's association with thromboembolic risk in membranous nephropathy is out. This systematic review & meta-analysis is amongst the 1st to demonstrate an association between serum anti-PLA2R Ab and thrombosis risk

[Arun Rajasekaran, MD, FACP, FASN, FNKF @Nephronpower]

@Nefrontera @TheLancet @UHN @UHN_Research @UofT @UofTNephrology @PKDFoundation @torra_roser @FPuigvert Congratulations!!

[NDT @NDTsocial]

🤩Check out our new Supplement on 'The Treatment Paradigm in IgAN Globally'

https://t.co/fzVCqCUawo

🧐Selected for you:

How should we approach the treatment of IgAN in 2025?

https://t.co/JKoaYtc6j5

#OpenAccess